

National Institute for Health and Care Excellence
IP2009 Caval valve implantation for tricuspid regurgitation

IPAC date: 13th June 2024

Com . no.	Consultee name and organisation	Sec. no.	Comments [sic]	Response
1.	Consultee 1 MEDIRA GmbH	Overview study 5 table 3	see Wild MG, 2022 - figure 3 on page 287 Baseline NYHA class 1:0% NYHA class 2: 4.8% NYHA class 3: 85.7% NYHA class 4: 9.5 %	Thank you for your comments. These figures have been amended in table 3 in the overview.
2.	Consultee 1 MEDIRA GmbH	Overview study 5 table 3	worth to mention that there was an improvement compared to baseline at baseline 0% of the patients were in NYHA class 1 and 4.8% were in NYHA class 2 but 85.7% in NYHA class 3 and 9.5% in NYHA class 4 see Wild MG, 2022 figure 3, page 287	Thank you for your comments. The text on page 18 in the overview have been amended.
3.	Consultee 1 MEDIRA GmbH	Overview Validity and generalisability	TRILLIUM	Thank you for your comments. The spelling error on page 22 of the overview have been amended.
4.	Consultee 2 British Cardiovascular Society	Not specified	No comments but I agree with the recommendations	Thank you for your comments.
5.	Consultee 3 Edwards LifeSciences	Not specified	No comments but I agree with the recommendations	Thank you for your comments.

"Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees."